Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Consider key factors when choosing expense tracking software, including compatibility, features, and security. Make an informed decision with our step-by-step guide.
20,557 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
The Baupost founder made a bold, selective move: trim a large Alphabet stake and pivot to a fintech name that slumped...
Investors are weighing Plug Power's turnaround against hydrogen hype. This guide breaks down the signals, risks, and ...
Cardano has weathered wild crypto cycles before. This guide lays out credible scenarios for 2030, explains what could...
A famous bear and a renowned economist throw down over where stocks go next. One foresees a milestone like 8,250 on t...
A major asset manager boosted its stake in Boot Barn, signaling confidence in the westernwear retailer. This piece br...
The AI rally around optics stocks like Lumentum has turned heads. But a single red flag can derail gains. This guide ...
Discover what Universal (UVV) 2026 earnings mean for investors. This plain-English guide breaks down performance driv...
When a growth stock slides after earnings, it can shake your confidence. This guide explains why oddity tech stock pl...
SpaceX IPO chatter has investors buzzing and critics worried. This piece breaks down why the hype could outpace reali...
A Monday rebound lifted the Nasdaq and S&P as chipmakers regain momentum after Friday's sell-off. This guide breaks d...
Meta Platforms has hovered around a pivotal level. This guide weighs the pros, cons, and real-world steps to decide i...